Bank Of Montreal Cardiol Therapeutics Inc. Transaction History

Bank Of Montreal

$192 Billion
Q1 2025

A detailed history of Bank Of Montreal transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Bank Of Montreal holds 50,079 shares of CRDL stock, worth $67,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,079

Previous 50,000 0.16%

Holding current value

$67,105

Previous $64,000 25.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.96 - $1.46 $75 - $115	79 Added 0.16%	50,079 $48,000
Q3 2024 Nov 13, 2024	SELL	$1.83 - $2.48 $204 - $277	-112 Reduced 0.22%	50,000 $99,000
Q2 2024 Aug 14, 2024	BUY	$1.67 - $2.97 $187 - $332	112 Added 0.22%	50,112 $101,000
Q1 2024 May 13, 2024	SELL	$0.88 - $2.06 $47,941 - $112,226	-54,479 Reduced 52.14%	50,000 $90,000
Q4 2023 Feb 08, 2024	SELL	$0.67 - $1.0 $4,472 - $6,675	-6,675 Reduced 6.01%	104,479 $87,000
Q3 2023 Nov 01, 2023	SELL	$0.76 - $1.19 $779 - $1,219	-1,025 Reduced 0.91%	111,154 $100,000
Q2 2023 Aug 02, 2023	BUY	$0.45 - $0.97 $9,980 - $21,513	22,179 Added 24.64%	112,179 $99,000
Q1 2023 Jun 13, 2024	BUY	$0.47 - $0.81 $28,425 - $48,987	60,479 Added 120.96%	110,479 $54,000
Q4 2022 Feb 01, 2023	BUY	$0.48 - $1.0 $36,129 - $75,269	75,269 Added 510.96%	90,000 $45,000
Q3 2022 Nov 10, 2022	BUY	$1.02 - $1.41 $15,025 - $20,770	14,731 New	14,731 $15,000
Q2 2022 Aug 11, 2022	SELL	$1.03 - $2.05 $8,992 - $17,898	-8,731 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.25 - $2.31 $10,913 - $20,168	8,731 New	8,731 $13,000

Others Institutions Holding CRDL

# of Institutions

Shares Held

7.81M

Call Options Held

25.9K

Put Options Held

1.7K

View Full List

About Cardiol Therapeutics Inc.

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $83M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

More about CRDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account